

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

1. (Currently Amended) A composition comprising a plurality of oncofetal antigen (OFA) epitopes that specifically stimulate T cytotoxic lymphocytes in a mammal, and a carrier, wherein said composition does not comprise any OFA epitope that specifically stimulates T suppressor cells.
2. (Original) The composition of claim 1, wherein said carrier is an adjuvant.
3. (Original) The composition of claim 1, further comprising an adjuvant.
4. (Original) The composition of claim 1, wherein said carrier comprises a vesicle.
5. (Original) The composition of claim 4, wherein said vesicle comprises a liposome.
6. (Original) The composition of claim 1, wherein each of said epitopes is attached to a lipophilic group.
7. (Original) The composition of claim 1, further comprising at least one OFA epitope that specifically stimulates T helper lymphocytes.
8. (Original) The composition of claim 7, wherein said at least one OFA epitope that specifically stimulates T helper lymphocytes is attached to a lipophilic group.
9. (Original) The composition of claim 7, comprising at least two OFA epitopes that specifically stimulate T helper lymphocytes.
10. (Currently Amended) The composition of claim 7, wherein said at least one OFA epitope that specifically stimulates T helper lymphocytes has about 8 to about 30 amino acids.

11. (Currently Amended) The composition of claim ~~4~~ 10, wherein said at least one OFA epitope that specifically stimulates T helper lymphocytes has about 8 to about 12 amino acids.

12. (Original) A method for preparing an immunotherapeutic composition for use in a human, comprising: (a) identifying a plurality of oncofetal antigen (OFA) epitopes that specifically stimulate T cytotoxic lymphocytes in the human; and (b) formulating two or more of the epitopes identified in (a) with a carrier, thus forming the immunotherapeutic composition.

13. (Original) The method of claim 12, further comprising c) identifying a plurality of oncofetal antigen (OFA) epitopes that specifically stimulate T helper lymphocytes in the human, and wherein b) comprises formulating one or more of the OFA epitopes identified in c) with the two or more epitopes identified in a) and the carrier.

14. (New) The composition of claim 1, wherein said plurality of OFA epitopes stimulates different clones of T cytotoxic lymphocytes.

15. (New) The composition of claim 1, wherein each of said plurality of OFA epitopes is present in said composition as a mixture.

16. (New) The composition of claim 1, wherein said plurality of OFA epitopes are linked together, thus forming one peptide.

17. (New) The composition of claim 1, wherein said plurality of OFA epitopes is linked to a common core structure.

18. (New) The composition of claim 17, wherein said common core structure is a multi-branched lysine or arginine core.

19. (New) The composition of claim 1, wherein each of said plurality of OFA epitopes that specifically stimulate T cytotoxic lymphocytes comprises about 8-12 amino acid residues.

20. (New) The composition of claim 1, wherein said plurality of OFA epitopes that specifically stimulate T cytotoxic lymphocytes are selected from the group consisting of RTWEKLLL (SEQ ID NO:6), NTGQRAVL (SEQ ID NO:7), CNTDSPLR (SEQ ID NO:9), YVDIAIPC (SEQ ID NO:10), and GEWTAPAP (SEQ ID NO:8).

21. (New) The composition of claim 7, wherein each of said OFA epitopes that specifically stimulate T helper lymphocytes is selected from the group consisting of SPLRYVDIAI (SEQ ID NO:15), GEWTAPAPEF (SEQ ID NO:16), AQPEVADWSE (SEQ ID NO:17), QVPSVPIQQF (SEQ ID NO:18), SAAPTAQATE (SEQ ID NO:19), and TEWVGATTDW (SEQ ID NO:20).

22. (New) An oncofetal antigen (OFA) fragment comprising an epitope that specifically stimulates T helper lymphocytes in a mammal, wherein said composition does not comprise an OFA epitope that specifically stimulates T suppressor cells.

23. (New) A method of treating cancer in a mammal, comprising administering to a mammalian cancer patient the composition of claim 1.

24. (New) The method of claim 23, wherein said mammalian cancer patient is a human.